SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2026 / Cilt: 42 Sayı: 1

Current treatment approaches in patients with ankylosing spondylitis

Ankilozan spondilitli hastalarda güncel tedavi yaklaşımları

Bilal Elbey
Pages
123–127
Publication Date
2015-05-09
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This manuscript is focused that Current pharmacological treatments in patients with ankylosing spondylitis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatic disease that mainly affects sacroiliac joints and spine.
📊
Key Findings & Data:AS predominantly occurs more often in males and typically begins in the second or third decade.
💡
Conclusion & Impact:This manuscript is focused that Current pharmacological treatments in patients with ankylosing spondylitis
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Ankilozan spondilit · tedavi · tümör nekrozis faktör alfa inhibitörü

Abstract

Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatic disease that mainly affects sacroiliac joints and spine. AS predominantly occurs more often in males and typically begins in the second or third decade. The mainstay of therapy in AS are nonsteroidal anti-inflammatory drugs, which reduce inflammation and pain. Disease modifying antirheumatic drugs (DMARD) did not have enough evidence to prove their effect in AS treatment. The use of DMARD may not sufficient to improve the treatment and symptoms. Currently, TNF-blockers such as, Golimumab Etanersept Adalimumab İnfliksimab have promising results in the treatment of AS. TNF-blockers improve the clinical signs and symptoms, and improve the patients’ physical function and quality of life. This manuscript is focused that Current pharmacological treatments in patients with ankylosing spondylitis

Özet

Ankilozan spondilit (AS) başlıca sakroiliak eklemler ve omurgayı etkileyen kronik, inflamatuar bir romatizmal hastalık olarak, daha çok erkeklerde sıklıkla 2. ve 3. On yılda ortaya çıkan bir hastalıktır. AS’li hastalarda tedavinin temelini ağrı ve inflamasyonu azaltan nonsteroid anti-inflamatuar ilaçlar (NSAİİ) almaktadır. Modifiye edici antiromatizmal (DMARD) ilaçlar, AS hastalığın tedavisinde etkinliği kanıtlanamamıştır. DMARD’ların kullanımı semptomların iyileştirilmesinde yeterli bulunmamıştır. Son zamanlarda anti tümör nekrozis faktör (TNF) blokerleri olan Golimumab, Etanersept, Adalimumab, İnfliksimab gibi ajanlar AS tedavisinde umut verici sonuçlar vermektedir. TNF blokerleri AS hastalarının fiziksel işlevlerinde, yaşam kalitesinde ve semptomlarında iyileşme sağlamaktadır. Bu yazı AS’li hastaların güncel farmakolojik tedavisi üzerine odaklanmıştır. Anahtar kelimeler: Ankilozan spondilit, tedavi, tümör nekrozis faktör alfa inhibitörü, hastalık modifiye edici ilaç- lar

🔖

Cite This Article

Elbey, B. (2015). Current treatment approaches in patients with ankylosing spondylitis. Dicle Tıp Dergisi, Cilt: 42 Sayı: 1, 123–127. https://doi.org/10.5798/diclemedj.0921.2015.01.0546

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (127)

  1. van der Linden S, van der Heijde D. Ankylosing spondylitis.
  2. Clinical features. Rheum Dis Clin North Am 1998;24:663-, vii.
  3. Weisman MH RJ, Heijde D. Ankilozan Spondilit ve Spondiloartropatiler.
  4. Ankara: Veri Medikal Yayıncılık; 2008.
  5. Dougados M, Dijkmans B, Khan M, et al. Conventional treatments
  6. for ankylosing spondylitis. Annals of the rheumatic diseases, 61 Suppl 3:iii 40-50.
  7. Lavie F, Pavy S, Dernis E, et al. Pharmacotherapy (excluding
  8. biotherapies) for ankylosing spondylitis: development of recommendations
  9. for clinical practice based on published evidence
  10. and expert opinion. Joint Bone Spine 2007;74:346-352.
  11. Kwan D, William R. Bartle, and Scott E. Walker. The effects of
  12. acetaminophen on pharmacokinetics and pharmacodynamics
  13. of warfarin. J Clin Pharmacol 1999;9: 68-75.
  14. Şahin E. Farmakolojik ajanlar. Fiziksel Tıp ve Rehabilitasyon
  15. Pratik El Kitabı. Tan CJ, editör. Şendur ÖF, Çeviri ed. 2.baskı
  16. İstanbul: Güneş Tıp Kitabevleri;2008. p.333-357.
  17. Melli M, Kayaalp SO. Non-Steroidal antiinflamatuar ilaçlar.
  18. Kayaalp SO (Editör). Rasyonel Tedavi Yönünden Tibbi Farmakoloji
  19. Baskı. Ankara: Hacettepe-Taş;2005 p.837-870.
  20. Maugars Y, Mathis C, Berthelot JM, et al: Assessment of
  21. the efficacy of sacroiliac corticosteroid injections in spondylarthropathies:
  22. a double-blind study. Brit J Rheumatol;35:767-770.
  23. van den Berg R, Baraliakos X, Braun J, van der Heijde D. First
  24. update of the current evidence for the management of ankylosing
  25. spondylitis with non-pharmacological treatment and nonbiologic
  26. drugs: a systematic literature review for the ASAS/
  27. EULAR management recommendations in ankylosing spondylitis.
  28. Rheumatology 2012;51:1388-1396.
  29. Braun J, Pham T, Sieper J, et al: International ASAS consensus
  30. statement for the use of anti-tumour necrosis factor agents
  31. in patients with ankylosing spondylitis. Ann Rheum Dis;62:817-824.
  32. Ozgocmen S, Akgul O, Altay Z, et al: Expert opinion and key
  33. recommendations for the physical therapy and rehabilitation
  34. of patients with ankylosing spondylitis. Int J Rheum Dis;15:229-238.
  35. Brooks P. Slow acting anti rheumatic drugs and cytotoxic
  36. agents. In: Schumacher HR, ed. Primer on the Rheumatic Diseases.
  37. Atlanta: Arthritis Foundation; 1993. p303-6
  38. Zochling J, van der Heijde D, Dougados M, Braun J: Current
  39. evidence for the management of ankylosing spondylitis: a systematic
  40. literature review for the ASAS/EULAR management
  41. recommendations in ankylosing spondylitis. Ann Rheum Dis;65:423-432.
  42. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major
  43. clinical response (BASDAI 50) to tumour necrosis factor
  44. α blockers in ankylosing spondylitis. Ann Rheum Dis,;63:665-670.
  45. Braun J. V, Van Den Berg R, Baraliakos X, et al. 2010 update
  46. of the ASAS/EULAR recommendations for the management
  47. of ankylosing spondylitis. Ann Rheum dis 2011;70: 896-904.
  48. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010
  49. Update of the international ASAS recommendations for the
  50. use of anti-TNF agents in patients with axial spondyloarthritis.
  51. Annals of the rheumatic diseases 2011;70:905-908.
  52. van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing
  53. Spondylitis Study for the Evaluation of Recombinant Infliximab
  54. Therapy Study G: Efficacy and safety of infliximab in
  55. patients with ankylosing spondylitis: results of a randomized,
  56. placebo-controlled trial (ASSERT). Arthrit Rheum;52:582-591.
  57. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing
  58. spondylitis with infliximab: a randomised controlled multicentre
  59. trial. The Lancet 2002;359:1187-1193.
  60. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant
  61. human tumor necrosis factor receptor (etanercept) for treating
  62. ankylosing spondylitis: a randomized, controlled trial. Arthrit
  63. Rheum 2003; 48:3230-3236.
  64. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety
  65. of golimumab in patients with ankylosing spondylitis: results
  66. of a randomized, double-blind, placebo-controlled, phase III
  67. trial. Arthrit Rheum 2008; 58:3402-3412.
  68. Braun J, Davis J, Dougados M, et al. First update of the international
  69. ASAS consensus statement for the use of anti-TNF
  70. agents in patients with ankylosing spondylitis. Ann Rheum
  71. Dis 2006; 65:316-320.
  72. Saag KG, Teng GG, Patkar NM, et al. American College of
  73. Rheumatology 2008 recommendations for the use of nonbiologic
  74. and biologic disease-modifying antirheumatic drugs in
  75. rheumatoid arthritis. Arthrit Care Res 2008;59:762-784.
  76. Black R A, Rauch CT, Kozlosky CJ, et al. A metalloproteinase
  77. disintegrin that releases tumour necrosis factor-R from cells.
  78. Nature 1997;385:729-733.
  79. Pay S. Romatizmal Hastalıklarda Anti-TNF İlaç Kullanımı.
  80. Turkiye Klinikleri J Med Sci, 2006;26:430-440.
  81. Gorman JD, Sack, K E, Davis JC Jr. Treatment of ankylosing
  82. spondylitis by inhibition of tumor necrosis factor α. N Engl J
  83. Med 2002;346:1349-1356.
  84. Dvis JC, Webb A, Lund S, Sack K, Result from an open-label
  85. extension study of etanercept in ankylosing spondylitis. Art
  86. Rheum 2004;51:302-104
  87. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and
  88. safety of etanercept after readministration in patients with active
  89. ankylosing spondylitis. Rheum 2005;44:342-348.
  90. Den Broeder AA, Saxne T, Heinegård D, et al. Long term antitumour
  91. necrosis factor α monotherapy in rheumatoid arthritis:
  92. effect on radiological course and prognostic value of markers
  93. of cartilage turnover and endothelial activation. Ann Rheum
  94. Dis 2002; 61:311-318.
  95. U.S Food and Drug administration, Full prescribing information,
  96. Adaliumab.2008. Available at:www.fda.gov.
  97. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor
  98. antagonist mechanisms of action: a comprehensive review.
  99. Pharmacol Ther 2008;117:244-279.
  100. Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers
  101. in patients with ankylosing spondylitis and non-radiographic
  102. axial spondyloarthritis: a meta-analysis. Ann Rheum Dis
  103. doi:10.1136/ 2014-205322 [Epub ahead of print]
  104. Patel Aarat M, and Larry W. Moreland. “Certolizumab pegol:
  105. a new biologic targeting rheumatoid arthritis. Ann Rheum Dis;6: 855-866.
  106. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action
  107. of certolizumab pegol (CDP870): In vitro comparison with
  108. other anti-tumor necrosis factor α agents. Inflamm Bowel Dis;13:1323-1332.
  109. Evans Ashley T, Lee SD. “A review and expert opinion of the
  110. use of certolizumab for Crohn’s disease. Expert Opin Biol
  111. Ther 2012; 12:363-370.
  112. Landewé R, Braun, J, Deodhar A, et al. Efficacy of certolizumab
  113. pegol on signs and symptoms of axial spondyloarthritis
  114. including ankylosing spondylitis: 24-week results of a double-blind
  115. randomised placebo-controlled Phase 3 study. Ann
  116. Rheum Dis 2013;73:39-47.
  117. Dhillon S: Certolizumab pegol: a review of its use in patients
  118. with axial spondyloarthritis or psoriatic arthritis. Drugs;74:999-1016.
  119. Dis 2006;65:316-320.
  120. Davis JC. Ankylosing Spondylitis In: Koopman WJ, Moreland
  121. LW (eds). Arthritis and Allied Conditions. A Textbook
  122. of Rheumatology Lippincott Williams and Wilkins P. 2005
  123. p.1319-1333.
  124. Braun Jv, Van Den Berg R, Baraliakos X, et al.: 2010 update
  125. of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
  126. Landewé R, Braun, J, Deodhar A, et al. Efficacy of certolizumab
  127. Braun Jv, Van Den Berg R, Baraliakos X, et al.: 2010 update